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Total chemical synthesis and high-resolution crystal structure of
the potent anti-HIV protein AOP-RANTES
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Background:  RANTES is a CC-type chemokine protein that acts as a
chemoattractant for several kinds of leukocytes, playing an important pro-
inflammatory role. Entry of human immunodeficiency virus-1 (HIV-1) into cells
depends on the chemokine receptor CCR5. RANTES binds CCR5 and inhibits
HIV-1 entry into peripheral blood cells. Interaction with chemokine receptors
involves a distinct set of residues at the amino terminus of RANTES. This
finding was utilized in the development of a chemically modified
aminooxypentane derivative of RANTES, AOP-RANTES, that was originally
produced from the recombinant protein using semisynthetic methods.
Results: AOP-RANTES has been produced by a novel total chemical synthesis
that provides efficient, direct access to large amounts of this anti-HIV protein
analog. The crystal structure of chemically synthesized AOP-RANTES has been
solved and refined at 1.6 Å resolution. The protein is a dimer, with the amino-
terminal pentane oxime moiety clearly defined.
Conclusions: Total chemical synthesis of AOP-RANTES provides a convenient
method of producing the multi-milligram quantities of this protein needed to
investigate the molecular basis of receptor binding and antiviral activity. This
work provides the first truly high-resolution structure of a RANTES protein,
although the structure of RANTES was known from previous nuclear magnetic
resonance (NMR) determinations.
Introduction
Chemokines are a diverse family of numerous small
(8–10 kDa) proteins that mediate a wide range of inflam-
matory responses in humans. These proteins are secreted at
the site of injury by many types of tissue cells, including
platelets, and frequently act as chemoattractants for a
variety of blood cells. Chemokines display a conserved
pattern of cysteine residues and are categorized into two
major subgroups, CC and CXC, depending on the sequence
of two key cysteine residues near the amino terminus of
the proteins. RANTES (regulated on activation normal
T cell expressed and secreted) is a 9 kDa CC chemokine
protein that acts as a chemoattractant and activating agent
for a broad range of immune system cells, such as mono-
cytes, T lymphocytes and eosinophils, but not neutrophils 
[1]. It is suggested to play a role in certain inflammatory
disorders, such as endotoxemia [2] and rheumatoid arthri-
tis [3]. RANTES binds to and signals through a number
of chemokine receptors, namely CCR1 [4–8], CCR3 [7],
CCR4 [9] and CCR5 [10–12]. Other CC chemokines, such
as MIP-1a and MIP-1b, can compete for binding to each of
the RANTES receptors. This competition is not surprising,
as their amino-acid sequences and tertiary structures are
quite similar. Because cells possess more than one type of
chemokine receptor, a complicated modulation of effects
can arise by the cross-networking of receptors and chemo-
kine ligand interactions.
The chemokine receptor CCR5 is a seven-transmembrane
G-protein-coupled receptor that has been identified as the
principal coreceptor for human immunodeficiency virus-1
(HIV-1) entry into peripheral blood cells. Because CCR5
acts as a coreceptor for HIV-1 uptake into mononuclear
cells, the binding of RANTES to CCR5 and the subse-
quent internalization of the chemokine–receptor complex
can block the initial infection by the virus [13,14]. Recently,
it was shown that chemical modification of RANTES at the
amino terminus produced a potent antagonist of HIV-l
entry into macrophages and other peripheral blood lympho-
cytes mediated by CCR5 [15]. In that work, based on the
observation that Met-RANTES (a derivative of RANTES
in which a methionine residue precedes the normal amino-
acid sequence) acted as a receptor antagonist, the protein
AOP-RANTES was prepared from recombinantly expressed
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Research Paper 43RANTES by semisynthetic methods [16]. Mild periodate
oxidation of the l-amino 2-ol moiety in the amino-terminal
serine of the folded disulfide-containing RANTES protein
molecule generated a glyoxal functionality; subsequent
chemoselective reaction with aminooxypentane was used
to form an oxime bond, generating the modified protein
[n-pentyl-O-N = CHCO][desSer1]RANTES [15].
Here, we report a novel total chemical synthesis that pro-
vides more efficient, direct access to large amounts of AOP-
RANTES. In a retrosynthetic sense, AOP-RANTES was
first envisioned as the unfolded polypeptide chain, which
was, in turn, divided into an amino-terminal segment, the
peptide AOP-RANTES (2–33)-a-thioester and a carboxy-
terminal segment, RANTES (34–68). This approach allowed
us to use native chemical ligation [17] to join these
unprotected peptide segments at the central Lys33–Cys34
sequence by reaction in aqueous solution at neutral pH
(Figure 1). After preliminary experimentation, we devised a
practical route for the incorporation of the AOP moiety, and
the amino-terminal segment was further retrosynthetically
divided into the peptide moiety comprising residues 2–33
and the oxime-containing moiety (compound 1 , Figure 1) to
provide a practical route to the desired protein molecule.
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Figure 1
Synthetic scheme for the preparation of AOP-
RANTES by means of native chemical ligation
of unprotected peptide in aqueous solution.
The two shaded residues show the native
chemical ligation site at Lys33–Cys34. Single-
letter amino-acid code is used.
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Stepwise SPPSWe used the resulting high-purity chemically synthesized
AOP-RANTES protein for X-ray crystallography to deter-
mine the three-dimensional structure of the molecule.
The structure of recombinant RANTES in solution was
previously determined independently by two groups [18,19],
but many questions about the structure were left unan-
swered in these medium-quality nuclear magnetic reso-
nance (NMR) studies. Specifically, the positions of the
first five residues of the amino terminus and several of the
residues at the carboxyl terminus were not defined at all,
and the orientation of the two monomers within the dimer
was not well defined. In this paper, we report the use of X-
ray crystallography to reveal the structure of a RANTES
protein in much greater detail. The majority of the struc-
ture remains similar to the NMR models, as shown by
comparison to the high-resolution (1.6 Å) crystal structure
of AOP-RANTES described here. Furthermore, in elec-
tron-density maps of the crystalline protein, the amino ter-
minus of AOP-RANTES is clearly bound in a hydrophobic
depression on the surface of the protein molecule.
Results and discussion
Chemical synthesis of the AOP-RANTES (2–68) polypeptide
Synthesis of the peptide segments was accomplished in a
straightforward manner using stepwise solid phase peptide
synthesis (SPPS) [20]. The amino-terminal segment AOP-
RANTES (2–33)-a-thioester was prepared on a thioester-
generating resin [21], using highly optimized Boc chemistry
SPPS [22]. At the last step in the synthesis of this segment,
the modified amino terminus was generated by on-resin
reaction of RANTES (2–33) with compound 1 preacti-
vated as the HOAt (1-hydroxy-7-azabenzotriazole) ester
to give AOP-RANTES (2–33)-a-thioester-resin. This reac-
tion proceeded quantitatively, with none of the starting
material RANTES (2–33) detected by electrospray ion-
ization–mass spectrometry (ESI–MS) after cleavage and
deprotection. Several other routes for the incorporation of
the oxime moiety were also explored, but with unsatisfac-
tory results. Synthesis of the carboxy-terminal peptide
segment RANTES (34–68) was carried out according to
published protocols [22]. Both peptide segments were
synthesized on a 0.25 mmol scale of starting aminoacyl-
resin. Following deprotection and cleavage (anhydrous
hydrogen fluoride, p-cresol (5% v/v), 0°C, 1 h), the pep-
tides were purified using reverse-phase high-pressure liquid
chromatography (RP–HPLC) in good yield: greater than
100 mg quantities of each purified segment were obtained
from a single synthesis.
AOP-RANTES (2–33)-a-thioester (25 mmol) and RANTES
(34–68) (27 mmol) were reacted at pH 7 in aqueous buffer
containing 6 M GuHCl as a chaotropic agent. Thiophenol
(0.5% v/v) was added to the ligation mixture to ensure that
cysteine residues were present in the reduced form and to
catalyze the reversal of unproductive thioester formation 
[23]. The amino-terminal segment, AOP-RANTES (2–33)-
a-thioester, was added in portions to minimize insolubility
due to aggregation and consequent poor reaction. The
ligation reaction was monitored using analytical RP–HPLC
and ESI–MS and was shown to have gone to completion
after 16 h (Figure 2b). No significant side reactions were
observed for ligation using this functionalized peptidyl-
lysine-a-thioester (Figure 2). Purification of the ligation
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Figure 2
Native chemical ligation of AOP-RANTES (2–33)-a-thioester and
RANTES (34–68) in aqueous solution at pH 7. The ligation reaction is
shown at: (a) 0 and (b) 16 h. The ligation reaction was monitored by
injecting 1 ml aliquots of the ligation solution on a C4 RP–HPLC
column with a gradient of 5–65% acetonitrile versus water containing
0.1% TFA, over 30 min. Detection was at 214 nm. (c) Characterization
of the purified ligation product. Analytical RP–HPLC chromatogram
with an inset showing ESI–MS of AOP-RANTES (2–68)–[(SH4)]:
observed mass, 7904.5 ± 0.6 Da; calculated mass (average isotope
composition), 7905.1 Da.
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Chemistry & Biologysolution by semipreparative RP–HPLC gave the ligated
polypeptide product AOP-RANTES (57.8 mg, 7.3 mmol,
30% recovered yield based on peptide segments). The yield
is significantly reduced compared with similar chemical-
ligation synthesis of native RANTES, which may be attrib-
uted to reduced recovery in the reversed-phase purification
due to the increased hydrophobicity of the AOP-poly-
peptide. The reduced polypeptide was characterized by
ESI–MS (observed mass, 7904.5 ± 0.6 Da; calculated mass,
average isotope composition, 7905.2 Da).
Folding and characterization
Folding and disulfide formation was carried out at pH 8 by
dissolving the purified polypeptide AOP-RANTES (2–68)–
[(SH)4] in an aqueous buffer of 2 M GuHCl, 100 mM Tris
containing 8 mM cysteine and 1 mM cystine. After gentle
stirring overnight, near-quantitative folding was obtained
(Figure 3a). Compared with the reduced polypeptide chain,
the folded product gave a sharp peak that eluted earlier on
an analytical RP–HPLC column, consistent with the for-
mation of a folded disulfide-cross-linked protein. In com-
parison with the reduced polypeptide, using ESI–MS, this
product showed a loss of 3.3 ± 1.2 mass units, consistent
with the formation of the expected two disulfides in the
folded protein molecule. Purification by semipreparative
RP–HPLC produced the protein AOP-RANTES (32 mg,
4.0 mmol, 55% yield based on unfolded polypeptide, 16%
yield based on peptide segments) in greater than 95%
purity (as determined by analytical RP–HPLC;
Figure 3b). The product was characterized further using
ESI–MS (observed mass 7901.2 ± 0.6 Da; calculated mass,
average isotope composition, 790l.2 Da).
The correct formation of the protein tertiary structure was
confirmed using NMR spectroscopy. Under the conditions
used (pH 3.7, ~1 mM protein), native RANTES is mainly a
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Figure 3
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Folding/disulfide formation. The purified polypeptide AOP-RANTES
(2–68)-[(SH)4] was stirred overnight at pH 8 in 2 M GuHCl in the
presence of 8 mM cysteine and 1 mM cystine. (a) Analytical RP–HPLC
chromatogram of the total crude folding products obtained. For the major
product, the retention time is 1.22 min earlier than the reduced
polypeptide, which is consistent with folding/disulfide formation.
(b) Characterization of purified synthetic AOP-RANTES. Analytical
RP–HPLC chromatogram with an inset showing ESI–MS of AOP-
RANTES: observed mass, 7901.2± 0 6 Da; calculated mass (average
isotope composition), 7091.15 Da. (c) 1H NMR measurements on the
synthetic protein AOP-RANTES (two-dimensional TOCSY experiment
performed at 600 MHz). The data show that a single conformation
predominates and are consistent with the canonical chemokine fold. The
annotations refer to the backbone assignments made on this sample.dimer [18]. As shown in Figure 3c, it was possible to assign,
in most cases, single cross-peaks in the total correlation
spectroscopy (TOCSY) spectrum to particular residues of
AOP-RANTES, demonstrating that a single conformation
predominates. Some evidence of a second conformation is
present, but this is also seen for the native RANTES and
arises from the presence of the monomeric form at low
concentration. Moreover, the chemical shifts of assigned
residues are nearly identical to those of the equivalent
residues in native RANTES, which demonstrates that
both proteins have very similar structures. The evidence for
correct formation of the protein tertiary structure was
further provided by the crystal structure (see below) and by
the ability of synthetic AOP-RANTES to completely
inhibit CCR5-dependent fusion of HIV-1 M-tropic Env
proteins gp120–gp41 with an ED50 of ~l nM in the cell
fusion assay using HeLa-CD4-CCR5-LTRLacZ and HeLa-
EnvADA cell lines (L.P., unpublished observations). In con-
trast, chemically synthesized RANTES with an unmodified
covalent structure had an ED50 of > 100 nM in the same
assay. These results are consistent with the observations
reported using recombinant RANTES and the recombi-
nant-derived semisynthetic AOP-RANTES [15].
Crystal structure of AOP-RANTES
AOP-RANTES prepared by total chemical synthesis was
crystallized using the hanging drop method by ammo-
nium-sulfate precipitation from a pH 4.5 solution. Small,
high-quality crystals were obtained. The structure of
AOP-RANTES was determined at 1.6 Å resolution, using
data collected with synchrotron radiation on beamline
X9B at the National Synchrotron Light Source (NSLS),
Brookhaven National Laboratory. Phases were obtained by
molecular replacement using the structure of Met-RANTES
(D.H. and J.L., unpublished observations). The positions
for all atoms could be defined by electron density, except
for the sidechain of Lys45 in monomer B, which has been
modeled in two alternate conformations. The amino termi-
nus, from the AOP moiety to residue Thr7, is clearly
defined (Figure 4) and packs against the noncrystallograph-
ically related monomer, with the AOP group bound within
a hydrophobic depression on the surface (Figure 5). The
fold of the AOP-RANTES monomer is similar to that of
other CC and CXC monomers, forming a three-stranded
antiparallel b sheet flanked by a carboxy-terminal a helix
(Figure 6). A short b sheet (b1) is formed between the
monomers from residues Thr8 to Cys10, finishing with a
long loop between Cys11 and Pro20 that stretches over the
molecule. After a short 310 helix (Arg21–His23), the main
b sheet is formed by Ile24–Tyr29 (b2), Val39–Thr43 (b3)
and Gln48–Ala51 (b4). Residues Lys56–Glu66 form the
carboxy-terminal a helix (a1), with residues Met67 and
Ser68 in an extended conformation. The loop between b2
and b3 contains a type III reverse turn (Ser31–Cys34); the
loop between b3 and b4, a distorted type I reverse turn
(Thr43–Asn46); and the loop between b4 and a1, a type I
reverse turn (Asn52–Lys55). Secondary structure elements
were defined using the program DSSP [24].
The contacts between monomers that are involved in
creating the dimer are minimal. Aside from the antiparal-
lel  b sheet formed by residues Thr8–Cys10 and the
AOP-linked amino termini, hydrogen bonds are formed
between Ser5(O) and Cys50¢(N), Asp6(N) and Gln48¢(O)
and Thr7(OG1) and Gln48¢(OE1). Also, there are several
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Figure 4
Electron density contoured at 1.2 s surrounding the AOP group,
Pro2 and Tyr3. The figure was made using MOLSCRIPT [39] and
Raster3D [40].
Figure 5
Close-up of the AOP 1 moiety. The AOP group contacts the
noncrystallographically related monomer at a hydrophobic depression
formed between the phenolic ring of Tyr14, the backbone atoms of
Ala13 and Phe12, the Cbs of Cys11, Asn36 and Pro37 and the Cg of
Thr30. The figure was made using MOLSCRIPT [39] and Raster3D [40].solvent-mediated hydrogen-bond bridges across the dimer
interface, connecting the loops between b2 and b3. Because
of loose packing between the monomers, a gap between
Phe12 and Phe12¢ is filled with a solvent molecule that
alternates between two positions in the crystal.
The conformation of the AOP group, Pro2 and Tyr3 is
slightly different in the two monomers. This difference can
be explained by a crystal contact in one of the monomers.
There are contacts between the peptide Pro2–Tyr3 of
monomer B and the symmetry-related ring of Tyr29, which
cause the amino terminus to push closer to the protein.
There are no contacts between the amino terminus of
monomer A and crystallographically related molecules,
however. Comparison of the amino termini from both
monomers shows the amino terminus of monomer A to be
better resolved and more highly ordered than monomer B,
with clearer density and lower temperature factors. The
crystal contacts of monomer B seem to disrupt the close
packing of the AOP group, and the conformation of the AOP
group in monomer A suggests an unbiased conformation.
Comparison of AOP-RANTES crystal structure to RANTES
NMR structures
There is very little difference in the secondary structure
between the crystal structure of AOP-RANTES, described
here and the NMR structures of native RANTES [18,19],
aside from assignment discrepancies at the ends of sec-
ondary structure elements. The root mean square deviation
(rmsd) values for superpositioning the backbone atoms of
AOP-RANTES residues 10–68 onto the equivalent atoms of
the 1RTO [18] and 1HRJ [19] structures are 1.0 and 1.3 Å,
respectively. The amino terminus (residues 1–10) moves
significantly in the overlay of AOP-RANTES on these
NMR structures, however (Figure 7). In contrast to the
RANTES NMR structures, in which the conformation of
the first five residues was not determined at all and several
carboxy-terminal residues are extensively disordered, the
AOP group, Pro2 and Tyr3 are seen quite clearly in the
AOP-RANTES crystal structure (Figure 4). The amino
termini wrap around the neighboring monomer, rather than
being more exposed to the solvent. The conformation of the
disulfide bridge between Cys10 and Cys34 is different for
the AOP-RANTES structure; although this bridge makes a
left-handed turn in all three structures, it is slightly dis-
torted in the 1RTO structure [18] and very distorted in
the 1HRJ model [19]. Because of the movement of Cys10,
changes between the NMR and crystal structures are
noticeable in the loop between b2 and b3, probably due to
the disulfide link between Cys10 and Cys34. There are
also several flipped peptide bonds between residues 31 and
36. Although the hydroxyl group of Thr30 is hydrogen
bonded to Ala38(N) in the NMR structures, the donor
hydroxyl oxygen is replaced by the carbonyl oxygen of
Thr30 in the crystal structures. This replacement buries the
sidechain into the protein and allows the loop to pack more
tightly against the protein. The differences between the
NMR models and the crystal structure might be due, in part,
to the relatively small amount of information afforded by the
solution spectroscopic protein structure determinations,
resulting in insufficient geometric constraints; the flexibility
of the protein might also play a role in these differences.
The largest differences are found in the dimer interface.
The sparse contacts between the monomers seem to allow
the dimer to flex, as seen in a comparison of the AOP-
RANTES dimer with the NMR structures of RANTES.
This flexibility seems to be inherent to the molecule,
because much larger differences between quaternary struc-
tures of RANTES were reported in the NMR models 
[18,19] and in the structures of a related CC chemokine,
MCP-1, observed in different crystal forms [25]. Although
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Figure 6
Overall structure of AOP-RANTES. The
dimer is shown here as it appears in the
asymmetric unit of the crystal structure.
Secondary-structure elements as labeled
were determined using the program DSSP 
[24]. The figure was made using the program
RIBBONS [41].the two monomers are linked through a short b sheet
by residues Thr8–Cys10, the relative orientations of the
monomers to each other are quite different. The dimeric
structure of AOP-RANTES is more compact than the
NMR structure, as reflected in the total buried surfaces.
AOP-RANTES buries 20% of the total monomeric solvent-
accessible surface on dimerization (monomer A = 5125 Å2,
monomer B = 4917 Å2, dimer = 8081 Å2), whereas the NMR
structures bury only 14% in the 1RTO model (monomer
A = 5314 Å2, monomer B = 5316 Å2, dimer = 9186 Å2) [18]
and 16% in the 1HRJ model (monomer A = 5451 Å2,
monomer B = 5429 Å2, dimer = 9142 Å2) [19]. The differ-
ence in the buried surface area between AOP-RANTES
and RANTES is due mainly to the tight fit between the
Pro2 and AOP groups wrapped around the surface of the
neighboring monomer. Although it is questionable whether
the monomer or dimer is the active form of the molecule, it
is known that at physiological pH RANTES can form
higher-order oligomers at high concentration [18] and in the
presence of glycosaminoglycans [26].
It has been shown in many studies that the amino terminus
of RANTES and other CC chemokines plays a crucial role
in the binding to and activation of chemokine receptors.
Truncations and alterations of the amino terminus give rise
to chemokine antagonists of various potency [27–29], as well
as inhibiting the infection of primary human macrophages
by HIV-1 in vitro [15]. Yet the exact role of the AOP group
in this effect is not known, but could be due to an increase
of affinity for the receptor, a decrease in receptor activa-
tion and/or an inhibition of receptor recycling [14,30]; all of
these effects would arise from some unknown interaction
between the chemokine and the receptor. Another possi-
bility includes a change in transfer to the cell surface as
mediated by glycosaminoglycans [26], although the binding
to glycosaminoglycans has been shown to be mediated pri-
marily by positively charged residues on a surface far from
the amino terminus [31].
The attachment of the AOP moiety to the amino termi-
nus alters the chemical nature and surface features of the
RANTES molecule; this could give rise to any of the
possible scenarios described above. The crystal structure
of AOP-RANTES shows the amino terminus to be clearly
defined and bound to the surface as compared with the
disordered amino terminus of native RANTES. The
sequestration of the amino terminus from solution to the
surface might therefore disallow specific interactions
with chemokine receptors. Alternatively, the presence of
the AOP group might disturb the monomer/dimer equi-
librium, which might or might not play a role in receptor
binding and activation [32]. Without a complete under-
standing of chemokine receptor activation, it is difficult
to state the reasons for the antagonist properties of AOP-
RANTES. Further studies of other RANTES derivatives
would be helpful in evaluating different hypotheses.
The availability of reliable synthetic methods should
facilitate these investigations greatly.
Significance
In this paper, we have described a convenient total chemi-
cal synthesis of high-purity AOP-RANTES on a multi-
milligram scale. These large amounts of protein are
essential to fully characterize the properties of this potent
anti-HIV chemokine derivative in animal models and
are necessary for structural analysis using 1H nuclear
magnetic resonance (NMR) and X-ray crystallography.
The synthetic polypeptide folded to give a homogeneous
protein species. The synthetic protein crystallized and dif-
fracted X-rays to high resolution (better than 1.6 Å). The
secondary structure of synthetic AOP-RANTES is very
similar to that of recombinant RANTES, as shown by
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Figure 7
Overlay of the crystal structure of AOP-RANTES on the two available
NMR structures of native, recombinant RANTES. As can be seen, the
monomer–monomer orientation in the dimer is very different between
the crystal structures and the NMR structures. AOP-RANTES is shown
in blue, 1RTO [18] in green, and 1HRJ [19] in red. This figure was
made using RIBBONS [41].comparison of the crystal structure with NMR structures.
Robust synthetic access to modified forms of RANTES
will enable the systematic application of the principles of
medicinal chemistry to refining the properties of this
important protein molecule. Such refinement will be of
great value in the search for improved CCR5 receptor
antagonists and will facilitate the development of agents to
block HIV-1 entry into peripheral blood cells, the primary
infective step in AIDS.
Materials and methods
Synthesis of the aminooxypentane-glyoxal oxime 1
Aminooxypentane TFA salt (550 mg, 2.53 mmol), glyoxylic acid monohy-
drate (210 mg, 2.28 mmol) and pyridine (410ml, 5.06 mmol) in methanol
(10 ml) were heated under reflux for 2 h. The volatiles were removed in
vacuo and the resulting oil was extracted with ethyl acetate. Combined
extractions were washed with 10% citric acid and water, then dried in
the presence of sodium sulfate. The volatiles were removed in vacuo to
give oxime 1 as a colorless solid.
Synthesis of the peptide segment
Peptides were synthesized using highly optimized Boc SPPS protocols 
[22]. Boc amino acids were used with the following sidechain protec-
tion: Arg(Tosyl), Asn(Xanthyl), Asp(OcHxl), Cys(4MeBzl), Glu(OcHxl),
His(DNP), Lys(2ClZ), Ser(Bzl), Thr(Bzl), Trp(formyl) and Tyr(BrZ). AOP-
RANTES (2–33)-a-thioester was synthesized on a thioester-generating
resin [21] with compound 1 coupled as the preactivated HOAt ester for
5 h at room temperature as the last step in the synthesis. RANTES
(34–68) was synthesized on a Boc-Ser(Bzl)OCH2-Pam resin. After com-
pletion of the chain assembly, the peptides were simultaneously cleaved
and deprotected from the resin by using anhydrous hydrogen fluoride
containing 5% p-cresol for 1 h at 0°C. The crude peptides were purified
on a C4 RP-HPLC column (linear gradient of 15–55% acetonitrile and
H2O containing 0.1% TFA for 53 min). Fractions were analyzed by
ESI–MS, and those of the correct mass were pooled and lyophilized
[AOP-RANTES (2–33)-a-thioester: observed mass, 4178.1± 0.77 Da;
calculated mass, 4178.6 Da (average isotope composition); RANTES
(34-68): observed mass, 4098.0± 0.50 Da; calculated mass, 4097.8 Da
(average isotope composition)].
Synthesis of AOP-RANTES (2–68)–[(SH)4]
RANTES (34–68) (111 mg, 27 mmol) was dissolved in 6 M GuHCl,
200 mM phosphate (pH 7) containing 0.5% thiophenol and ligated
with AOP-RANTES (2–33)-a-thioester (104 mg, 25 mmol) at a final
peptide concentration of 20 mg ml–1. The ligation reaction was
allowed to proceed to completion with stirring for 16 h. Excess 2-mer-
captoethanol was added to the ligation solution to reduce partially oxi-
dized ligated product prior to purification on a C4 RP–HPLC column
(linear gradient of 20–60% acetonitrile and H2O containing 0.1% TFA
for 60 min). Fractions were analyzed by ESI–MS, and those of the
correct mass were pooled and lyophilized [AOP-RANTES (2–68)–
[(SH)4]: observed mass, 7904.5 ± 0.4 Da; calculated mass, 7905.2
Da (average isotope composition)].
Folding
AOP-RANTES (2–68)–[(SH)4] was dissolved at 1 mg ml–1 in 2 M
GuHCl, 100 mM Tris (pH 8) containing 8 mM cysteine and 1 mM cystine.
After gentle stirring overnight, the protein solution was purified on a C4
RP–HPLC column (linear gradient of 10–50% acetonitrile and H2O
containing 0.1% TFA for 60 min). Fractions were analyzed using
ESI–MS, and those of the correct mass were pooled and lyophilized
[AOP-RANTES: observed mass, 7901.2 ± 0.6 Da; calculated mass,
7901.2 Da (average isotope composition)].
NMR Measurements
For NMR experiments, 5 mg of protein was dissolved in 0.54 ml of
25 mM sodium acetate buffer (pH 3.7) containing 60 ml of D2O.
Experiments were conducted at 37°C. To assess the conformational
homogeneity of the synthesized protein, a TOCSY experiment was
performed using the DIPSI-2 sequence [33], with water suppression
by the double pulse field gradient spin echo technique [34]. The
mixing time was 40 ms; acquisition times were 70 ms in the first
dimension and 170 ms in the second dimension. For each of 512
complex increments, 64 scans were collected giving a total experi-
mental time of 27 h. Data were processed using macros written
within the program FELIX95 (MSI Inc., San Diego, CA). Assignments
were made by analyzing the TOCSY spectrum in combination with a
proton–proton nuclear Overhauser effect spectrum (data not shown).
A full assignment and interpretation of the data are underway (P.N.B.,
H.M., D.A.T and J.W., unpublished observations).
Crystallization and structure determination of AOP-RANTES
The lyophilized AOP-RANTES sample was resuspended in 10mM
sodium acetate (pH 4.6) at a concentration of 15 mg ml–1. 2 ml of this
protein solution was mixed with 2ml of precipitant [0.1 M ammonium
sulfate, 225 mM sodium succinate (pH 4.0), 275 mM 2-(N-morpholino)-
ethanesulfonic acid (pH 6.0), 15% ethanol]; due to the hydrophobicity of
AOP-RANTES, it was further diluted to 20ml with 16 ml H2O. This solu-
tion was then suspended over 1 ml of the same precipitant and left to
equilibrate for 3–4 weeks at 20°C.
Single crystals grew only to a small size (0.1 ´ 0.1 ´ 0.05 mm3), as
larger crystals became intertwined and were thus unusable. For diffrac-
tion experiments, the crystals were mounted on small fiber loops and
rapidly cooled in a 100K nitrogen stream, after washing the crystals
briefly in the precipitant solution described above (with the addition of
15% glycerol as a cryoprotectant). These small crystals diffracted to
only 2.5 Å on a rotating anode X-ray source (Rigaku RU200 generator
with a MAR345 image plate), with exposure at a rate of 20 min/degree
oscillation. Diffraction extending beyond 1.6 Å, however, was obtained
using synchrotron radiation (beamline X9B, NSLS), where a complete
data set was collected from a single crystal. The data were collected
using 1° oscillations, and individual reflections were integrated and
scaled using HKL2000 [35]. Statistics for the data are given in Table 1.
The phases were obtained by molecular replacement using the X-ray
structure of Met-RANTES (D.H. and J.L., unpublished observations). Ten
percent of the structure amplitudes was then partitioned into a test set to
monitor refinement using cross-validation [36]. These data were not used
during the refinement. After four rounds of refinement using X-PLOR 
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Table 1
Statistics for data collection and model refinement.
Wavelength (Å) 0.98
Resolution (Å) 20–1.6
Reflections (measured/unique) 74,936 (17,338)
a 23.635 Å
b  56.307 Å
c 94.030 Å
Space group P212121
Completeness 
(overall/highest resolution bin) 99.8/100.0 (1.60–1.66 Å)
*Rscale (overall/highest resolution bin) 0.043/0.196 
I/s(I) (overall/highest resolution bin) 31.8/7.5
†R factor/free R factor  0.167/0.241
‡rmsd: bonds (Å) 0.008
rmsd: angles (degrees) 1.4
Average temp. factor 
(protein atoms/all atoms, Å2) 19.53/23.75
Number of residues 134
Number of solvent/SO4
2– molecules 215/4
*Rscale = S|In–<I>|/S<I>. †R factor = S|{|Fo|-k|Fo|}|/S|Fo|; free
R factor = S(h)ÎT|{|Fo(h)|–k|Fc(h)|}|/S(h) ÎT|Fo(h)|, where T represents a
test set of reflections not used in the refinement. ‡rmsd, root mean
square deviation.[37], the R factor was 0.209 for data in the shell 8–2.4Å. The refinement
was expanded to 1.6 Å resolution, and after seven rounds of refinement
and model building, two AOP groups were introduced, and the model
included four sulfates, all residues (Pro2–Ser68), and 148 solvents,
yielding an R factor of 0.235. After three more rounds, which included
both X-PLOR and SHELX-97 [38], the final R factor was 0.167 and the
free R factor was 0.241 for the resolution range 20–1.6Å. Statistics for
the refinement and the final model are given in Table 1. The atomic coor-
dinates and structure factors for AOP-RANTES have been deposited
with the Protein Data Bank (accession number for the coordinates 1b3a
and r1b3asf for experimental structure factors).
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